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The IgE response has been associated with both allergic reactions and immunity to meta-
zoan parasites. Recently, we hypothesized that all environmental allergens bear structural
homology to IgE-binding antigens from metazoan parasites and that this homology defines
the relatively small number of protein families containing allergenic targets. In this study,
known allergen structures (Pfam domains) from major environmental allergen families were
used to predict allergen-like (SmProfilin, SmVAL-6, SmLipocalin, SmHSP20, Sm triosephos-
phate isomerase, SmThioredoxin, Sm superoxide dismutase, SmCyclophilin, and Sm phos-
phoglycerate kinase) and non-allergen-like [Sm dynein light chain (SmDLC), SmAldolase
SmAK, SmUbiquitin, and Sm14-3-3] proteins in Schistosoma mansoni. Recombinant anti-
gens were produced in Escherichia coli and IgG1, IgG4, and IgE responses against them
measured in a cohort of people (n=222) infected with S. mansoni. All allergen-like antigens
were targeted by IgE responses in infected subjects, whilst IgE responses to the non-
allergen-like antigens, SmAK, SmUbiquitin, and Sm14-3-3 were essentially absent being of
both low prevalence and magnitude.Two new IgE-binding Pfam domain families, not previ-
ously described in allergen family databases, were also found, with prevalent IgE responses
against SmDLC (PF01221) and SmAldolase (PF00274). Finally, it was demonstrated that
immunoregulatory serological processes typically associated with allergens also occurred
in responses to allergen-like proteins in S. mansoni infections, including the production of
IgG4 in people responding with IgE and the down-regulation of IgE in response to increased
antigen exposure from S. mansoni eggs. This study establishes that structures of known
allergens can be used to predict IgE responses against homologous parasite allergen-like
molecules (parallergens) and that serological responses with IgE/IgG4 to parallergens mir-
ror those seen against allergens, supporting our hypothesis that allergenicity is rooted in
expression of certain protein domain families in metazoan parasites.
Keywords: schistosomiasis mansoni, allergenicity, IgE, IgG4, parasite allergens, metazoan parasite, helminth
proteins
INTRODUCTION
The role of IgE in allergic immune responses is well estab-
lished and extensive research has characterized ≈3000 known
allergens (1, 2). Further analysis of known allergens has
shown that they occupy a highly restricted set of 255 pro-
tein domains, defined in the Pfam database by their structure
and function, representing <2% of all known protein domain
families (3). Furthermore just 10 Pfam protein domains rep-
resent no fewer than 40% of the 995 molecular protein aller-
gens described in the Allfam allergen family database. These
“top 10” families containing the greatest number of different
individual allergenic proteins are (in order of frequency) Pro-
lamin, EF-hand, Tropomyosin, CAP (CRISP/Antigen-5/PR-1),
Subtilisin-like serine proteases, Lipocalin, Profilin, Bet v 1,
Expansin, and Cupin (3). The reasons for the predominance
of a restricted molecular subset and the principles underly-
ing “What makes an allergen an allergen?” are currently not
known. Many different biochemical properties of proteins have
been suggested to be determinants of allergenicity including
size, solubility, hydrophobicity, protein fold stability, oligermer-
ization, venom toxicity, post-translational modifications, and
protease activity (2, 4). However, none of these factors indepen-
dently describe all allergens or indeed differentiate satisfactorily
between allergens and non-allergens, for example, not all aller-
gens are proteases and there are many examples of non-allergenic
proteases.
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We have therefore suggested a new paradigm, which defines a
common characteristic of potentially allergenic structural protein
families, and explains why they are restricted in number (5). Potent
IgE-mediated immune responses are seen during infections with
metazoan parasites, including both helminth (worm) endopara-
sites and ectoparasites such as arthropod ticks. Moreover, there
is a growing body of evidence to suggest that the IgE-mediated
immune response, which is a recently evolved immune mech-
anism found only in mammals, helps protect against infection
with metazoan parasites (6–13). Furthermore, given that meta-
zoan parasites have similar cell biology to the metazoan host, it
would be expected that potential targets for antibody responses
would exclude proteins with high identity to their equivalents in
the host. This appears to be more marked with IgE than other
antibody isotypes and most environmental allergens share <70%
identity with their human equivalents (14).
Examination of the “top 10” allergen families in the context
of the human antibody responses against infecting metazoan
parasites revealed examples of parasite proteins with known IgE-
binding domains or “parallergens” in three allergen families; EF-
hand domains in Tegumental-Allergen-Like (TAL) proteins from
schistosomes (15), Tropomyosin proteins in filarial nematodes
and schistosomes (16, 17), and CAP protein domains in hook-
worm nematodes (18). A further five families; Subtilisin-like serine
protease, Lipocalin, Profilin, Bet v 1, and Cupin families, contain
metazoan parasite homologs with the potential to be targeted by
IgE during human parasitic infections (5). Additionally there are
many known immunogenic proteins, with potential IgE-binding
activity, within the most abundant schistosome proteins that may
have homology to known allergens (19–22).
When attempting to identify IgE responses to parasite proteins
it is important to consider the effects of chronic helminth infec-
tion in humans, and the shifts between IgE and IgG4 isotypes that
occur during long-term exposure (23). Responses to parallergens
in helminth-infected subjects may result in the down-regulation
of IgE antibodies and the production of IgG4 to the same aller-
genic epitopes (15, 24). This shift is well-documented in allergy,
especially in specific immunotherapy (SIT), where constant low-
level exposure to a specific allergen results in increased IgG4 and
decreased IgE levels (25, 26). In individuals with schistosomiasis
mansoni, the expression of proteins across the S. mansoni life cycle
and their localization in specific tissues may be important in deter-
mining the levels of exposure of a protein to the immune system
and the corresponding antibody responses. The human life cycle
stages of S. mansoni include infective skin-penetrating cercaria,
host tissue-migrating schistosomule, blood-dwelling adult worms,
and eggs (27). Due to a number of immune evasion mechanisms,
protein antigens in cercaria, schistosomules, and adult worms are
generally sequestered away from immune system and are only
exposed upon the death of the adult worms, which may take
between 3 and 10 years (28). On the other hand, antigens present
in eggs (thousands of which are released daily) are continuously
exposed to the immune system during the death of eggs that have
failed to escape the host and become trapped in tissues, a process,
which usually takes 1–2 weeks. Indeed studies in schistosomiasis
mansoni endemic areas on the SmTAL family of EF-hand paral-
lergens have shown that for antigens expressed exclusively in the
adult worm stage of the parasite, such as SmTAL1 and SmTAL3,
IgE responses only develop naturally over time as adult worms
die or during treatment with praziquantel (PZQ), which damages
adult worms and reveals cryptic antigens (24). Conversely, for
antigens expressed strongly in eggs, such as SmTAL2, IgE antibod-
ies are seen only during early infection (children <5 years) with
IgE responses down regulated and replaced with IgG4 antibody
responses in older individuals (24, 29). Therefore in determining
the “allergen-like” properties of S. mansoni predicted parallergens
it is important to consider their expression in eggs/adult worms,
as well as both IgE and IgG4 antibody levels to each antigen.
We therefore hypothesize that known IgE-binding domains
may be used to predict the protein targets of allergy-like responses
in individuals infected with S. mansoni, including targeting by
IgE, the induction of regulatory responses such as targeting by
IgG4 and the down-regulation of IgE in response to continuous
exposure of antigens during infection. In this study, we now show
that known allergen structures can indeed be used to predict IgE-
binding and allergy-like responses against recombinant S. mansoni
parallergens in an infected human cohort from a schistosomiasis
mansoni endemic area of Uganda.
MATERIALS AND METHODS
PARASITE MATERIAL
A Puerto Rican strain of S. mansoni was used in this study.
RNA was isolated and extracted from cercaria and adult worms
as previously described (30). RNA integrity was verified using
a Bioanalyser (Agilent Technologies, Bracknell, UK). cDNA was
prepared from 1µg total RNA using random hexamers (Sigma-
Aldrich, Gillingham, UK) and Superscript II reverse transcriptase
according to the manufacturer’s instructions (Life Technologies,
Paisley, UK).
BIOINFORMATIC ANALYSIS
Hidden Markov Models (HMMs) of Pfam domains associated
with the “top 10” allergen families listed in Allfam1 were used
to search the Uniprot database2 to identify any S. mansoni pro-
teins containing the relevant Pfam domains (3, 31). Similarly Pfam
domains associated with S. mansoni proteins abundant in human
life cycle stages [as identified by proteomics (21)] were used to
search Allfam for functional sequence similarity to families of
known allergens.
To compare known parasite and allergen structures, protein
sequences of S. mansoni proteins with known 3D structure were
used to search Allergome3 for allergens with similar sequence.
Allergens with an E-value cut-off of <1× 10−4 were searched for
corresponding known 3D structures in Protein Data Bank4. Pro-
tein models were generated using MODELLER v9.10 (32) and
LSQMAN5 was used to perform protein structural alignments
by least squares super-positioning with the quality of the models
assessed by root mean squared deviation (RMSD).
1www.meduniwien.ac.at/allergens/allfam/
2http://www.uniprot.org
3http://www.allergome.org/
4http://www.ebi.ac.uk/pdbe/
5http://xray.bmc.uu.se/usf/lsqman_man.html
Frontiers in Immunology | Microbial Immunology February 2015 | Volume 6 | Article 26 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Farnell et al. Predicted parasite allergens in schistosomiasis
MOLECULAR CLONING
SmTAL1 (GenBank M37003.1), SmTAL2 (GenBank M67506.1),
Sm triosephosphate isomerase (SmTPI) (GenBank M83294.1),
and SmTropomyosin II (GenBank KC904504.1) were produced
using the pGEX family of plasmids during other studies (17,
24, 33). pGEX-KG plasmid containing Sm dynein light chain
(SmDLC) (GenBank U55992.1) was a kind gift from Karl Hoff-
mann (University of Aberystwyth). The SmVAL-6 CAP domain
(amino acids 1–145 of full-length SmVAL-6, GenBank AY953433)
was cloned into the pET-30a vector. All other antigens were
cloned in the pGEX-KG vector. Gene sequences were derived
from GenBank and primers containing unique restriction enzymes
sites were designed using Primer3Plus (Table S1 in Supplemen-
tary Material)6. PCR to generate gene specific coding sequences
was performed using Phusion High Fidelity DNA polymerase
(Thermo Fisher Scientific, Reading, UK) in a Tetrad 2 thermal
cycler (MJ research/Bio-Rad, Hemel Hempstead, UK). PCR prod-
ucts and plasmids were digested with the relevant pair of Fast-
Digest restriction enzymes (Table S1 in Supplementary Material).
Additionally, plasmids were treated with FastAP (Thermo Fisher
Scientific) to prevent self-ligation and ligation was performed
using T4 DNA ligase (Thermo Fisher Scientific). Ligated plas-
mids were used to transform chemically competent DH5α E. coli
cells by heat shock. Sanger sequencing was used to characterize
cloned sequences. The sequences of SmLipocalin, Sm phospho-
glycerate kinase (SmPGK), SmCyclophilin, and SmAldolase were
found to be identical to previously cloned and sequenced cDNAs;
GenBank Accession numbers M60895.1, L36833.1, L46884.1, and
L38658.1. For molecules that had not been previously cloned
and sequenced or differed from previous submissions, sequences
were uploaded to GenBank with the following accession num-
bers; SmProfilin, KJ545485; Sm14-3-3, KM281669; SmUbiqui-
tin, KM281670; SmAK, KM281671; SmThioredoxin, KM281672;
Sm superoxide dismutase (SmSOD), KM281673; and SmHsp20,
KM281674.
PROTEIN EXPRESSION AND PURIFICATION
SmTAL1, SmTAL2, SmTPI, and SmTropomyosin II were expressed
and purified as described previously (17, 24, 33). All other proteins
ligated into pGEX-KG were expressed and purified as follows.
Overnight cultures of TG2 E. coli containing the relevant plas-
mid were diluted 1:10, expanded to OD 0.4–0.8 and induced
for 3–5 h with 1 mM IPTG. For SmSOD, TG2 E. coli cultures
were also supplemented with 0.02 mM CuCl2 and 0.02 mM ZnCl2
and induced with 0.1 M IPTG as defined by Cardoso et al. (34).
Cells were lysed using a French Pressure Cell at ≈10,000 psi
and GST-fusion proteins isolated by affinity chromatography on
Glutathione Sepharose 4B using an AKTAprime plus (GE Health-
care, Amersham, UK) as per the manufacturer’s instructions.
Proteins were separated from their fusion partners by cleav-
age on Glutathione Sepharose using thrombin (GE Healthcare).
Contaminating GST-fusion partner and thrombin were removed
by incubation with Glutathione Sepharose 4B (GE Healthcare)
and benzamadine-agarose beads (Sigma-Aldrich), respectively.
6http://primer3plus.com
SmVAL-6 was purified using a combination NiNTA and Q-
Sepharose affinity chromatography as follows. Overnight cultures
of BL21(DE3) E. coli containing the SmVAL-6 construct were cul-
tured, induced, and lysed as above. Hexahistidine tagged proteins
were isolated by affinity chromatography on NiNTA-agarose using
an AKTAprime plus (GE Healthcare) as per the manufacturer’s
instructions. Bacterial protein contamination was removed by Q-
Sepharose ion exchange using a HiTrap Q (FF) column. Proteins
were separated by elution on a 0–1 M NaCl gradient, and fractions
containing only SmVAL-6 (120–350 mM NaCl) reserved. Proteins
were tested for GST and bacterial contamination by in-house
enzyme-linked immunosorbent assay (ELISA) assay using rabbit
anti-GST antisera (Sigma) and rabbit anti-E. coli lysate antisera as
previously described (24). Where required, MALDI fingerprint-
ing was performed by the Protein and Nucleic Acid Chemistry
facility (University of Cambridge Department of Biochemistry,
Cambridge, UK).
STUDY POPULATION
Venous blood samples were collected from volunteers living in
the fishing village of Namoni, on the shores of Lake Victoria
in the Mayuge district of South East Uganda. Transmission of
schistosomiasis was consistently high throughout the year and the
community received annual treatment as part of the Ugandan
national control program. Three hundred seventy-two individuals
(6–40 years, 57% female, mean age 18) with detectable infection
(based on one stool sample, two Kato-Katz thick smears) were
randomly selected from the village. Blood samples were collected,
immediately prior to chemotherapy with PZQ (40 mg/kg body
mass) and 5 weeks post-treatment, into heparinized tubes. Plasma
was isolated by centrifugation at 2000× g for 5 min, then aliquoted
and stored at −80°C until use. Parasitological examinations were
carried out before treatment and at 5 weeks post-treatment (to
determine efficacy of treatment). For this study, we focused on
222 individuals (60% of total) for whom full serological and par-
asitological data were available (age 6–40 years, mean age 16 years,
59% female, pre-treatment prevalence of S. mansoni infection
was 98.2%).
ETHICS STATEMENT
The Ugandan National Council of Science and Technology pro-
vided ethical clearance. Forms were translated in the local language
and informed written assent was obtained from all adults and
written consent from the parents/legal guardians of all children
under 15.
ENZYME-LINKED IMMUNOSORBENT ASSAY
Antigen-specific IgG1, IgG4, and IgE levels were measured in the
plasma of infected individuals in duplicate by ELISA as described
previously (24). The following modifications were made for spe-
cific antigens used in this protocol. Each antigen was applied to
384 well plates and incubated overnight at 4°C or dried to the
plates at 37°C overnight as indicated in Table S2 in Supplemen-
tary Material. For each antigen, saturation coating concentrations
and conditions were determined using an in-house competitive
binding ELISA and were as shown in Table S2 in Supplementary
Material. Human plasma was diluted 1:40 for IgE assays and 1:100
for IgG isotypes.
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STATISTICAL ANALYSIS
Data management and statistical analysis was performed using
STATA for Mac version 12.1. Change in the magnitude of antibody
levels following treatment with PZQ were calculated as follows:
% change = 100
×
[
e x¯(ln(AbMagnitudepost−RX+0.01)−ln(AbMagnitudepre−RX+0.01))−1
]
Significance in the changes of magnitudes were calcu-
lated by Wilcoxon matched-pairs signed-ranks test. Preva-
lences/proportions of responders were calculated following the
application of assay sensitivity cut-offs (mean+ 3σ) determined
using sera from 26 normal European controls. Final cut-off values
were determined following correction for outliers (NES responses
greater than mean+ 3σ) using in iterative process in which out-
liers were removed and the threshold recalculated until no outliers
were found (Table S3 in Supplementary Material). Comparison
of proportions of individuals responding with IgE alone vs. those
responding with IgE and IgG4 together was performed by two-
sample test of proportions. Significance in the difference in of
antigen expression levels by microarray was calculated by one way
ANOVA with Bonferroni post-tests for antigen-to-antigen differ-
ences. Correlations between IgE and egg expression levels were
calculated using linear regression followed by Cook’s distance and
leverage-vs.-squared-residual plot regression diagnostics to assess
the impact of influential outliers. Regression diagnostics were
performed to determine that assumptions were valid including,
linearity, normal distribution of errors, and homoscedasticity of
variance.
RESULTS
IDENTIFICATION OF ALLERGEN-LIKE ANTIGENS IN S. MANSONI
Protein domain searches were used to identify S. mansoni pro-
teins with functional domain sequence similarity (similar Pfam
domains) to known allergens. Firstly, we searched for examples
of S. mansoni proteins with Pfam domain similarity to allergens
from the “top 10” Allfam allergen families. Proteins with sim-
ilarity to the EF-Hand, Profilin, CAP, Tropomyosin, Lipocalin,
and Subtilisin-like Serine Protease families listed in Allfam were
found in S. mansoni (Table 1), whilst examples of proteins in the
Bet v 1, Cupin, Expansin, and Prolamin families were not. Sec-
ondly, we searched for potential parallergens amongst the 32 S.
mansoni proteins that were identified in the proteomic study of
Curwen et al. (21) as being abundant in lifecycle stages found in
the human host. Twenty-four (75%) were found to have domains
with sequence similarity to known allergens (Table 2) whilst 8
(25%) did not.
From these two approaches, nine predicted parallergens were
selected for study, SmProfilin, SmVAL-6, SmLipocalin, SmThiore-
doxin, SmCyclophilin, SmTPI, SmSOD, SmPGK, and SmHSP20.
Additionally, 5 S. mansoni proteins were selected that were abun-
dant within the parasite, but were not predicted to be paraller-
gens, including SmAldolase, SmUbiquitin, SmDLC, SmAK, and
Sm14-3-3. Finally, known IgE target proteins, SmTAL1, SmTAL2,
and SmTropomyosin II produced for other studies were used as
positive controls (17, 24).
CLONING AND EXPRESSION OF ANTIGENS IN E. COLI
Recombinant forms of the antigens selected for cloning were
produced in E. coli. In the case of SmVAL-6 only the solu-
ble invariant N-terminal segment of the protein (amino acids
1–145) containing the CAP domain was expressed. For each
protein, coding sequences were cloned from parasite cDNA by
PCR. These were inserted into either the pGEX-KG or pET-
30a vector and sequenced. Following expression and exten-
sive purification molecular weights of the recombinant pro-
teins were estimated by SDS-PAGE (Figure 1); SmVAL-6,
19 kDa; SmLipocalin, 15.5 kDa; SmProfilin, 15 kDa; Sm14-3-3,
26 kDa; SmDLC, 12 kDa; SmCyclophilin, 20 kDa; SmAldolase,
41 kDa; SmPGK,45 kDa; SmHSP20,42 kDa; SmUbiquitin,16 kDa;
SmSOD 17 kDa; SmThioredoxin 10 kDa; SmTPI 27 kDa; and
SmAK 24 kDa. In the Sm14-3-3 sample, proteins observed at
approximately 18 and 8 kDa represent the C and N-terminal
(respectively) degradation products of full-length Sm14-3-3 as
confirmed by MALDI fingerprinting (data not shown). Assay by
ELISA confirmed that all recombinant proteins were free from sig-
nificant contamination from the GST-fusion partner and bacterial
antigens (data not shown).
IgE RESPONSES ARE PREVALENT AGAINST PREDICTED ALLERGEN-LIKE
MOLECULES
In order to determine the immunogenicity of the antigens, serolog-
ical responses were studied in detail. For each antigen, three anti-
body isotypes, IgE, IgG4, and IgG1, were measured in plasma from
an infected cohort living in a schistosomiasis mansoni endemic
area of Uganda. Previous studies have indicated that some anti-
gens may be sequestered within the adult worms and not exposed
Table 1 | Schistosoma mansoni antigens with functional sequence identity to abundant allergens.
Protein Pfam domain Pfam name Allergen family name (Allfam) UniProt identifier
SmTAL1 PF00036 EF-Hand EF-hand domain Q4TTW6
SmProfilin PF00235 Profilin Profilin G4VTE3
SmVAL-6 PF00188 Cysteine-rich secretory protein family CRISP/PR-1/venom group 5 allergen family G4V6N1
SmTropomysosin II PF00261 Tropomyosin Tropomyosin G4VN65
SmLipocalin PF00061 Lipocalin/cytosolic fatty-acid binding
protein family
Lipocalin G4M131
SmFurin-1 PF00082 Subtilase family Subtilisin-like serine protease G4VJB1
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Table 2 | Identification of allergen-like proteins in abundant proteins from S. mansoni as identified in proteomic studies by Curwen et al. (21).
Protein name Pfam domain Pfam name Allergen family name (Allfam) Uniprot accession
Sm Calponin PF00307 Calponin homology (CH) domain EB1 family G4M0V2
Sm Calreticulin PF00262 Calreticulin family Calreticulin family Q06814
Sm HSP20 (p40) PF00011 HSP20/alpha crystallin family HSP20 heat shock protein P12812
Sm Phosphoglycerate kinase PF00162 Phosphoglycerate kinase Phosphoglycerate kinase P41759
Sm Superoxide dismutase PF00080 Copper/zinc superoxide dismutase
(SODC)
Cu/Zn Superoxide dismutase Q01137
Sm GAPDH PF02800 Glyceraldehyde 3-phosphate
dehydrogenase, C-terminal domain
Glyceraldehyde 3-phosphate
dehydrogenase
P20287
Sm HSP86 PF00183 Hsp90 Protein Heat shock protein Hsp90 Q26582
Sm Aldehypde dehydrogenase PF00171 Aldehyde dehydrogenase family Aldehyde dehydrogenase G4LWI3
Sm Serpin-like protein PF00079 Serpin (serine protease inhibitor) Serpin serine protease
inhibitor
G4LZN6
Sm Triosephosphate Isomerase PF00121 Triosephosphate Isomerase Triosephosphate isomerase G4V6B9
Sm Cyclophilin PF00160 Cyclophilin type peptidyl-prolyl
cis-trans isomerase/CLD
Cyclophilin Q26565
Sm HSP70 PF00012 Hsp70 protein Heat shock protein Hsp 70 G4V8L4
Sm GST26 PF00043 Glutathione S-transferase,
C-terminal domain
Glutathione S-transferase G4LXF8
Sm GST28 PF00043 Glutathione S-transferase,
C-terminal domain
Glutathione S-transferase P09792
Sm Thioredoxin PF00085 Thioredoxin Thioredoxin Q8T9N5
Sm Taurocyamine kinase (ATP:GK) PF00217 ATP:guanido phosphotransferase,
C-terminal catalytic domain
ATP:guanido
phosphotransferase
P16641
Sm Enolase PF00113 Enolase, C-terminal TIM barrel
domain
Enolase G4VQ58
Sm FaBP/Sm Lipocalin PF00061 Lipocalin/cytosolic fatty-acid binding
protein family
Lipocalin P29498/G4M131
Sm Tropomyosin-1 PF00261 Tropomyosin Tropomyosin P42637
Sm Myosin LC PF13499 EF-hand domain pair EF-hand domain Q9Y1U7
Sm Calpain PF00036 EF-hand EF-hand domain P27730
Sm TAL3 PF00036 EF-hand EF-hand domain P91804
Sm TAL2 PF00036 EF-hand EF-hand domain P32070
Sm E16 PF00036 EF-hand EF-hand domain Q07167
Sm 14-3-3 homolog 1 PF00244 14-3-3 protein – Q26540
Sm 14-3-3 ε PF00244 14-3-3 protein – Q9U491
Sm Actin PF00022 Actin – P53470
Sm AK PF00406 Adenylate Kinase – P25824
Sm Dynein Light Chain PF01221 Dynein light chain type 1 – Q94758
Sm Ubiquitin PF00240 Ubiquitin family – Q6RYS0
Sm Aldolase PF00274 Fructose-bisphosphate aldolase
class-I
– P53442
Sm Elong F 1 PF00009 Elongation factor Tu GTP binding
domain
– Q94747
For proteins with functional similarity to known allergens the Allfam allergen family name is given.
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to the immune system (24). Therefore antibody levels were stud-
ied 5 weeks post-treatment with PZQ so as to observe immune
responses that may only be generated following worm damage or
death. It is recognized that the use of a single dilution of sera per
antibody isotype is a limitation of this study but it was a necessity
given the number of individuals and sera isotypes assayed.
All nine of the predicted parallergens including SmHSP20,
SmVAL-6, SmProfilin, SmThioredoxin, SmTPI, SmCyclophilin,
SmLipocalin, SmSOD, and SmPGK were found to be the target
of an IgE response both pre- and post-treatment (RX) with PZQ
within varying portions of the population (Figure 2A, I). The pro-
portions ranged from 59% post-RX for SmHSP20 to 4.1% pre-RX
for SmPGK. For these antigens, the magnitudes of IgE responses
ranged from 0.15 ng/ml for SmPGK pre-RX and 159.4 ng/ml for
SmVAL-6 post-RX (Table 3). IgE responses were also seen against
the positive control parallergens SmTAL1 and SmTropomyosin
II (Figure 2A, III). Significant boosts in the magnitude of IgE
responses following treatment occurred for SmProfilin, SmVAL-6,
SmHSP20, and SmDLC (Table 3).
Of the five antigens that did not contain known allergenic
domains, three of the antigens, SmAK, SmUbiquitin, and Sm14-3-
3 were found to have low prevalences of IgE responders; 1.3/3.1%,
2.7/0.9%, and 0.9/0.45% pre-/post-RX, respectively (Figure 2A,
II). Conversely SmDLC and SmAldolase had a relatively large pro-
portion of specific IgE responders; 34.2/51.3% and 31.1/27.9%
pre/post-RX, respectively. As shown in previous endemic study
populations that did not include young children (<5 years), IgE
responses to SmTAL2 were absent despite its similarity to allergens
from the EF-hand family (15, 24).
IgG4 RESPONSES ARE PREVALENT AGAINST ALLERGEN-LIKE
IgE-BINDING ANTIGENS
It has been suggested that production of IgG4 against S. man-
soni allergen-like proteins can be induced as part of the regulatory
response to IgE-mediated inflammation and should therefore be
considered as part of an allergy-like response (24). In this study,
IgG4 responses were observed against all of the IgE-binding anti-
gens studied both pre- and post-RX with PZQ (Figure 2B) with the
most prevalent against SmThioredoxin (75.2% pre-RX) and the
least against SmProfilin (5.9% pre-RX). Furthermore for the par-
allergens SmHSP20, SmDLC, SmThioredoxin, SmTropomyosin II,
SmAldolase, SmVAL-6, and SmTAL1 the majority of individuals
that produced an IgE response also produced an IgG4 response
against the same antigen with a significantly greater proportion of
individuals producing both IgE and IgG4 responses than an IgE
response alone (Figure 3). For SmAK and Sm14-3-3 to which low
prevalence IgE responses were observed, IgG4 responses were also
of low prevalence. Of note was SmTAL2, which despite the absence
of IgE responses was the target of specific IgG4 responses in 35 and
32% of the population pre-/post-RX, respectively. Similarly in the
case of SmUbiquitin, despite a low proportion of IgE responders
in the population, prevalent IgG4 responses occurred.
IgG1 RESPONSES ARE PREVALENT AGAINST RECOMBINANT
S. MANSONI PROTEINS
All of the antigens, both allergen- and non-allergen-like, were
found to elicit IgG1 responses in human infections both pre- and
FIGURE 1 | SDS-PAGE of recombinant antigens following expression
and purification. Proteins were run on a 4–12% gradient Bis-Tris gel and
stained with Coomassie Blue.
post-treatment with PZQ. IgG1 responses were found to be present
against all of the recombinant antigens ranging in prevalence from
6.3% post-RX for SmTropomyosin II to 70.7% pre-RX for SmTAL2
(Figure 2C). Magnitudes of IgG1 response amongst responders
were between 0.2µg/ml pre-RX for SmDLC and 151.1µg/ml pre-
RX for SmTropomyosin II (Table 3). Significant differences in
the magnitudes of IgG1 responses following treatment with PZQ
were seen for SmTAL1, SmVAL-6, SmCyclophilin, SmThioredoxin,
SmTPI, SmSOD, SmDLC, SmUbiquitin, SmAK, and Sm14-3-3
(Table 3).
PARALLERGENS AND ALLERGENS HAVE CLOSE CONFORMATIONAL
SIMILARITY
Confirmed S. mansoni parallergens with previously elucidated 3D
structures, SmLipocalin (1VYF), SmSOD (1TO4), and SmThiore-
doxin (2XBI), were compared for gross structural similarity to
allergens with known 3D structure including Dermatophagoides
farinae Der f 13 (2A0A), Solanum lycopersicum Superoxide
dismutase (3HOG), and Litopenaeus vannamei Thioredoxin
(3ZZX), respectively. All three proteins were found to have
overall structural similarity with their counterpart allergens
with RMSD scores of 0.9 Å, 0.6 Å, and 1.5 Å for SmThiore-
doxin/LvThioredoxin, SmSOD/SlSOD, and SmLipocalin/Der f 13,
respectively (Figure 4).
ANTIGENS ARE DIFFERENTIALLY TRANSCRIBED IN S. MANSONI ADULT
AND EGG LIFE CYCLE STAGES
Previous studies have suggested that differing levels of S. mansoni
antigen exposure may influence the prevalence and magnitude of
antigen-specific antibody responses (15, 24). Available microar-
ray data (35) show that all of the antigens in this study were
transcribed in adult worms (Figure 5A), and whilst transcription
was not equal across all antigens (SmThioredoxin and SmProfilin
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FIGURE 2 | Prevalence of IgE (A), IgG4 (B), and IgG1 (C) responses (with
95% binomial CIs), both pre- and post-treatment with PZQ to
recombinant antigens within the population (n=222). Prevalences/
proportions of responders were calculated following the application of assay
sensitivity cut-offs (mean+3σ) determined using sera from 26 normal
European controls. Proteins were grouped into predicted IgE-binding antigens
(I), antigens without known allergenic domains (II), and confirmed IgE-binding
antigens (III).
were found to be significantly lower in expression than all of
the antigens) there were no antigens for which transcription in
adult worms was very low or absent. Transcription of antigens in
eggs (Figure 5B) was more selective with some antigens showing
significantly lower expression than others (SmVAL-6, SmTAL1,
SmThioredoxin, SmDLC vs. all other antigens, p< 0.001) and
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Table 3 | Magnitudes of antibody responses against recombinant S. mansoni antigens in a population of 222 infected individuals as geometric
means (Ab magnitude+0.01) of IgG1, IgG4, and IgE for sub populations of individuals with responses to S. mansoni antigens either pre- or
post-treatment with PZQ.
Antigen IgE (ng/ml) IgG4 (µg/ml) IgG1 (µg/ml)
SmTAL1 Pre-RX 3.96 (0.79, 19.89) 0.09 (0.06, 0.14) 33.4 (23.1, 48.2)
Post-RX 17.7 (4.23, 73.87) 0.40 (0.23, 0.70) 50.7 (35.4, 72.6)
Boost 346.3% (n=42) 347.9% (n=76) 52.1% (n=72)
SmTAL2 Pre-RX 0 (0, 0) 0.20 (0.13, 0.30) 20.2 (15.8, 25.7)
Post-RX 0 (0, 0) 0.31 (0.18, 0.54) 15.5 (11.3, 21.3)
Boost 0% (n=0) 59.8% (n=96) −23.2% (n=169)
SmProfilin Pre-RX 0.19 (0.07, 0.54) 0.35 (0.10, 1.24) 71.9 (55.0, 94.0)
Post-RX 6.60 (2.65, 16.5) 1.09 (0.32, 3.78) 82.8 (60.9, 112.6)
Boost 3345.0% (n=64) 207.9% (n=19) 15.1% (n=96)
SmVAL-6 Pre-RX 19.5 (8.75, 43.6) 0.44 (0.24, 0.83) 8.5 (5.4, 13.4)
Post-RX 159.4 (105.5, 240.8) 11.0 (7.00, 15.2) 25.1 (15.6, 40.2)
Boost 715.7% (n=88) 2386.6% (n=117) 194% (n=154)
SmTropomyosin II Pre-RX 114.6 (88.1, 149.0) 8.11 (6.49, 10.1) 151.1 (115.6, 197.6)
Post-RX 93.5 (63.3, 137.9) 8.68 (6.95, 10.8) 117.4 (92.2, 149.7)
Boost −18.4% (n=24) 7.0% (n=160) −22.3% (n=20)
SmLipocalin Pre-RX 3.68 (0.45, 30.1) 0.05 (0.03, 0.10) 8.1 (4.4, 14.7)
Post-RX 12.0 (1.84, 77.6) 0.03 (0.02, 0.06) 6.8 (3.6, 12.3)
Boost 224.9% (n=23) −34.0% (n=20) −16.1% (n=86)
SmThioredoxin Pre-RX 16.5 (5.34, 50.8) 9.60 (6.50, 14.2) 54.7 (28.7, 104.1)
Post-RX 16.7 (5.41, 51.6) 9.37 (6.23, 14.1) 8.2 (3.4, 19.7)
Boost 1.4% (n=62) −2.4% (n=181) −85.0% (n=112)
SmCyclophilin Pre-RX 0.23 (0.04, 1.35) 0.42 (0.22, 0.82) 80.2 (68.8, 93.6)
Post-RX 4.75 (1.09, 20.7) 0.46 (0.26, 0.82) 70.8 (61.8, 81.0)
Boost 1979.6% (n=25) 9.6 (n=36) −11.8% (n=44)
SmTPI Pre-RX 1.60 (0.57, 4.47) 0.44 (0.27, 0.71) 12 (8.0, 18.4)
Post-RX 1.49 (0.54, 4.13) 0.64 (0.40, 1.04) 1.9 (1.0, 3.8)
Boost −6.9% (n=41) 46.8% (n=88) −84.0% (112)
SmSOD Pre-RX 21.7 (11.7, 40.3) 0.30 (0.22, 0.40) 120.4 (103.5, 134.0)
Post-RX 18.6 (12.3, 28.1) 0.23 (0.17, 0.31) 97.7 (81.9, 116.6)
Boost −14.4% (n=24) −23.0% (n=144) −18.9% (n=75)
SmPGK Pre-RX 0.15 (0.04, 0.61) 0.32 (0.12, 0.83) 1.4 (0.8, 2.8)
Post-RX 0.78 (0.26, 2.36) 0.75 (0.26, 2.12) 1.7 (1.0, 3.2)
Boost 434.2% (n=18) 132.6% (n=66) 20.9% (n=97)
SmHSP20 Pre-RX 8.24 (4.54, 14.9) 297.5 (185.6, 477.0) 40.0 (22.9, 70.0)
Post-RX 22.7 (13.7, 37.7) 319.6 (207.7, 491.7) 71.8 (44.9, 114.9)
Boost 176.0% (n=147) 7.4% (n=160) 79.5% (n=157)
SmAldolase Pre-RX 3.64 (1.66, 7.98) 0.30 (0.22, 0.39) 64.9 (48.2, 87.2)
Post-RX 2.19 (0.95, 5.06) 0.29 (0.22, 0.39) 63.9 (49.1, 83.2)
Boost −39.8% (n=98) −1.7% (n=148) −1.7% (n=38)
SmDLC Pre-RX 32.4 (15.8, 66.3) 0.14 (0.09, 0.21) 0.2 (0.1, 0.3)
Post-RX 209.4 (144.1, 304.4) 0.49 (0.33, 0.73) 120.1 (80.2, 179.9)
Boost 546.7% (n=124) 248.0% (n=173) 70891% (n=147)
(Continued)
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Table 3 | Continued
Antigen IgE (ng/ml) IgG4 (µg/ml) IgG1 (µg/ml)
SmUbiquitin Pre-RX 3.78 (0.23, 61.3) 1.35 (0.71, 2.56) 13.4 (8.5, 21.1)
Post-RX 0.07 (0.00, 1.82) 0.59 (0.28, 1.25) 3.1 (1.6, 6.3)
Boost −98.0% (n=7) −56.0% (n=69) −76.6% (n=105)
SmAK Pre-RX 0.13 (0.01, 2.61) 0.08 (0.02, 0.28) 10.6 (6.5, 17.1)
Post-RX 2.93 (0.22, 39.1) 0.22 (0.10, 0.49) 2.0 (1.0, 4.0)
Boost 2118.1% (n=9) 172.3% (n=20) −81.4% (n=96)
Sm14-3-3 Pre-RX 2.33 (0.00, 309075) 0.84 (0.36, 1.94) 10.3 (5.9, 18.1)
Post-RX 0.10 (0.00, 2569) 0.21 (0.06, 0.72) 6.1 (3.1, 11.9)
Boost −95.5% (n=3) −75.2% (n=21) −41.3% (n=96)
Changes in Ab magnitudes were calculated as described in the Materials and Methods. Significant differences in the levels of antibodies pre- and post-RX (Wilcoxon
matched-pairs signed-ranks test p< 0.05) are highlighted in bold.
n, Number of responders in each group.
FIGURE 3 | Proportions of individuals responding with IgE alone, IgG4
alone, or IgG4 and IgE together post-treatment with PZQ.
Prevalences/proportions of responders were calculated following the
application of assay sensitivity cut-offs (mean+ 3σ) determined using sera
from 26 normal European controls. Two-sample test of proportions was used
to compare the prevalence of individuals responding with IgE alone vs. those
responding with IgE and IgG4 together (*p<0.05, **p<0.01, ***p<0.001).
Proteins were grouped into predicted IgE-binding antigens (I), antigens
without known allergenic domains (II), and confirmed IgE-binding
antigens (III).
some significantly higher than others (SmHSP20 vs. all other anti-
gens p< 0.001). SmVAL-6 and SmDLC, both transcribed at low-
levels in eggs (0.5 and 7.7% of adult levels, respectively) showed
marked boosts in antibody levels following treatment, whilst those
more strongly expressed in egg, such as SmSOD, SmUbiquitin, and
Sm14-3-3 (between 47.5 and 82.5% of adult transcription levels)
all showed marked decreases in antibody levels post-treatment
(Table 3).
ANTIGEN-SPECIFIC LEVELS OF IgE ARE NEGATIVELY CORRELATEDWITH
ANTIGEN EXPRESSION IN EGGS
In order to determine if constant exposure of antigens from the
death of short-lived eggs in host tissues influenced levels of IgE,
we compared the level of antigen expression in eggs with antigen-
specific IgE levels in infected individuals both pre- and post-
treatment with PZQ. As previous studies have demonstrated that
the age of infected individuals, their level of IgG4 antibodies and
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FIGURE 4 | Comparison of the structures of SmLipocalin,
SmThioredoxin, SmSOD with their respective IgE-binding
counterparts identified from Allergome. Parasite allergen-like molecules
were used to identify similar allergens by BLAST search of the Allergome
database. Identities of the matched allergens with the corresponding
E -values are shown below each matched pair. Structures were
superimposed using LSQMAN and the quality of the alignment assessed
by root mean squared deviation (RMSD). (A) Alignment of SmLipocalin
(1VYF, cyan) and Der f 13 (2A0A, green). (B) Alignment of SmSOD (1TO4,
cyan) and Tomato SOD (3HOG, green). (C) Alignment of SmThioredoxin
(2XBI, cyan) and White Shrimp Thioredoxin (3ZZX, green).
intensity of infection (as measured by number of eggs in feces) may
confound the levels of IgE antibodies, these variables were included
in univariate regression models explaining variation in IgE magni-
tude (Figure 6) (17, 29, 36–38). Regression diagnostics indicated
that SmHSP20 exerted undue influence over the effect of egg tran-
scription on IgE levels (Cook’s distance> 1) and was therefore
excluded from this model. Upon the exclusion of SmHSP20 this
analysis established that antigen-specific IgE magnitude prior to
treatment was significantly negatively correlated with transcrip-
tion levels for each antigen in eggs (β=−0.550, r2= 0.2739,
p= 0.038) an association that strengthened post-treatment with
PZQ (β=−0.716, r2= 0.3666, p= 0.013) as shown in Figure 6A.
None of the other confounding variables, including geometric
mean (GM) age, GM infection intensity, or GM IgG4 levels were
found to significantly correlate with IgE levels.
DISCUSSION
Allergy and atopic spectrum diseases have been extensively studied
over a number of decades providing a detailed description of many
of the protein allergens that are associated with IgE-mediated aller-
gic immune reactions (1, 3). We have suggested that the immune
responses associated with allergy are the by-product of the highly
evolved immune response to metazoan parasites, and that aller-
gens and metazoan IgE-binding proteins share similar structural
features, which define the immune responses produced against
them (5). To this end, we hypothesized that known protein aller-
gen structures could be used to predict IgE-binding proteins from
the metazoan parasite S. mansoni.
We used a bioinformatic approach to search for S. mansoni par-
allergen examples of abundant common allergens and to predict
parallergens in proteins abundant in S. mansoni. Nine potential
IgE-binding antigens were cloned in E. coli alongside, three known
IgE targeted S. mansoni antigens, and five other abundant S. man-
soni antigens that were predicted not to bind IgE due to the lack of
known similar proteins in allergy. We then tested if these antigens
FIGURE 5 | Differential transcription of antigens in S. mansoni adult
worms (A) and eggs (B) as determined by previously published
microarray studies (35). Levels of antigen transcription were expressed as
relative fluorescent units (RFU).
were targets for IgE, IgG4, and IgG1 in individuals infected with
the parasite.
IgE responses were prevalent against all of the predicted paral-
lergens, and against the known IgE target control antigens SmTAL1
and SmTropomyosin II. This study defines a novel set of antigens
that are targeted by IgE in plasma from individuals with schis-
tosomiasis mansoni, including SmProfilin, SmHSP20, SmPGK,
SmSOD, SmCyclophilin, and SmThioredoxin. Several of these
antigens are also the first examples of parallergens with similar-
ity to known environmental allergens from the Profilin, HSP20
heat shock protein, Cu/Zn Superoxide dismutase, and Thiore-
doxin allergen families, respectively. SmVAL-6 is a novel human
IgE-binding parallergen in S. mansoni and along with previously
identified hookworm Na-ASP-2 and SmVAL-4 parallergens is a
further example of a parallergen with structural similarity to aller-
gens from the CAP family (18, 39). IgE-binding to Cyclophilin
from Echinococcus granulosus has also been previously reported
in infected humans (40). IgE responses against SmTAL1 and
SmTropomyosin II have been previously reported in S. mansoni
endemic areas of Uganda, whilst responses against SmTPI and
SmLipocalin were described in a recent study on infected indvidu-
als from Brazil (15, 17, 19). Despite being a predicted IgE targeted
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FIGURE 6 | Relationships between antigen-specific natural log
normalized geometric mean (GM) IgE levels and transcription of antigen
in egg (A)*, natural log normalized GM IgG4 levels (B), GM age (C), or GM
infection intensity (D) in individuals that respond to either IgG4 or IgE
both pre- (open circles, short dashes) and post-treatment (filled circles,
long dashes) with PZQ to a given antigen (β, SE, and p value calculated
by linear regression). *SmHSP20 was excluded from this plot as it exerted
undue influence on the linear regression model (Cook’s distance > 1).
antigen, SmTAL2 was not targeted by IgE. Other studies on human
antibody responses against SmTAL2 in schistosomiasis mansoni
endemic areas have shown that SmTAL2 may be targeted by IgE
but only in early infection, which typically occurs in children under
the age of 5, an age group not present in our study (24, 29).
Of the five S. mansoni antigens without allergen family coun-
terparts, there was no strong evidence of IgE targeting of SmAK,
SmUbiquitin, or Sm14-3-3; IgE responses were essentially absent
from the cohort, being of both low prevalence and magnitude.
SmDLC and SmAldolase however, were both targets of preva-
lent IgE responses. Currently, the Allfam dataset used to identify
IgE-binding proteins in this study only identifies class II aldolases
(Pfam Acc. PF01116) as allergens, whilst SmAldolase is a class-I
aldolase (Pfam Acc. PF00274) with distinctive structure associ-
ated with a separate Pfam domain (41). However, recent proteomic
work has shown that a class-I Aldolase from maize (Zea mays) is
targeted by IgE in maize allergic individuals, confirming SmAl-
dolase as an allergen homolog (42, 43). Previous work on SmDLC
had indicated that it was not the target of an IgE response (15),
however that study used antigens that had been prepared under
denaturing conditions, which may have affected their antigenic-
ity. The evidence here that SmDLC is part of a novel class of
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IgE-binding proteins in S. mansoni, despite their absence from the
allergen databases, may point to an important difference between
allergens and some parallergens. In order to interact with the suf-
ferer, allergens require the stability to survive the environment
and cross mucosal barriers (44), whilst parallergens can be deliv-
ered directly into the blood and tissues by the parasite. Hence
some classes of parasite IgE-binding proteins, such as DLC, may
be absent from the allergy datasets as they are simply not seen by
the immune systems of atopic individuals. Additionally, as illus-
trated for SmAldolase, the Allfam dataset, whilst comprehensive,
is far from complete and it may be as more detailed proteomic
studies of known allergen sources are completed further novel
IgE-binding families are identified. For example, in a 2014 pro-
teomic study on maize allergens, 6 of the 11 novel allergens found
were not previously described in other allergenic sources and thus
far are not present as Allfam families (42).
In the case of antibody responses to allergens in patients under-
going SIT and parasite IgE-binding proteins in chronic infec-
tions, IgG4 is thought to be induced as part of a protective
anti-inflammatory regulatory response to IgE-mediated inflam-
mation (reviewed (45) and (23), respectively). IgG4 responses
were observed against all of the allergen-like antigens in this
study in varying amounts. For SmHSP20, SmDLC, SmThiore-
doxin, SmTropomyosin II, SmAldolase, SmVAL-6, and SmTAL1,
the majority of individuals that produced an IgE response against
a given antigen also produced an IgG4 response against the same
antigen providing further evidence for the role of IgG4 in a protec-
tive anti-inflammatory role in humans chronically infected with
S. mansoni. Prevalent IgG4 responses were also observed against
molecules with low prevalence IgE responses including SmTAL2
and SmUbiquitin. As discussed previously, it is thought that for
antigens expressed strongly in eggs, such as SmTAL2, IgE antibod-
ies are seen only during early infection (children <5 years) with
IgE responses down regulated and replaced with IgG4 antibody
responses in older individuals (24, 29). It is possible that this may
also occur for SmUbiquitin, which is also expressed strongly in
eggs, and that its absence from databases of known allergens is
due to a similar process in which exposure to Ubiquitin, which
is highly conserved in eukaryotes and abundant in other allergen
sources such as birch pollen (46, 47), in atopic individuals results
in down regulated IgE and up regulated IgG4.
Importantly, all of antigens tested were immunogenic, with dif-
fering proportions of infected individuals within the population
producing an IgG1 response against each of the antigens. For sev-
eral of these (SmPGK, SmSOD, SmLipocalin, SmTAL1, SmTAL2,
SmTropomyosin II, Sm14-3-3, SmTPI, and SmDLC), responsive-
ness has been shown previously in infected humans and mice (15,
17, 48–52). However, novel human IgG1 responses were described
to SmAK, SmUbiquitin, SmAldolase, SmHSP20, SmCyclophilin,
SmThioredoxin, SmVAL-6, and SmProfilin. Crucially for Sm14-3-
3, SmUbiquitin, and SmAK, to which IgE responses were low, a
prevalent IgG1 response was found, confirming that the low-level
of allergy-like responses was not due to poor immunogenicity.
Alignments of known parallergen and allergen structures
including examples of Superoxide dismutase, Thioredoxin, and
Lipocalin allergen families demonstrated that, despite relatively
low sequence identity between matched parallergens and allergens,
there was high gross structural similarity. This observation lends
further weight to our hypothesis, which suggests that the structural
similarity between allergens and metazoan parasite IgE-binding
molecules defines the restriction of allergen families to a small
proportion of structural domains. We predict that more extensive
bioinformatic, crystallographic, and serological studies of whole
parasite proteomes and the five remaining allergen super families
(Prolamins, Subtilisin-like serine proteases, Bet v1-like proteins,
Cupins, and Expansins) may reveal further parallergens in support
of this hypothesis.
Studies on the SmTAL family of antigens suggest that sequestra-
tion of antigens may influence their overall levels of exposure to the
immune system and consequently antibody levels (24). In schis-
tosomiasis, the death of eggs trapped in tissue has been suggested
to result in constant exposure of allergen-like molecules to the
immune system, whilst pharmacological damage of adult worms
results in exposure to sequestered antigens upon treatment with
PZQ (15, 24). Consistent with this IgE, IgG4 and IgG1 antibody
levels to both SmVAL-6 and SmDLC, antigens that are expressed
in adult worms but not eggs, boosted significantly following treat-
ment with PZQ. Conversely antigens expressed in both eggs and
adults, including SmSOD, Sm14-3-3, and SmUbiquitin had signif-
icant decreases in specific antibody levels 5 weeks post-treatment
with PZQ, which may be the result of decreased exposure to these
antigens as eggs are no longer being produced. Previous investiga-
tions of serological responses in SIT have indicated that prolonged
exposure to allergens may result in a decrease in serum IgE levels
(26, 53). We found that for the majority of antigens in the study the
relative level of expression of antigens in egg was negatively corre-
lated with levels of IgE to that antigen. However, levels of SmHSP20
specific IgE were high despite being the molecule being strongly
expressed in eggs. Intriguingly, the levels of IgG4 to SmHSP20
were between 30 and 35 times greater than next highest antigen-
specific IgG4 levels (SmThioredoxin). Therefore we suggest that,
for the majority of antigens, constant exposure to antigens due
to the death of eggs results in a down-regulation of IgE against
those antigens with the effective dose of antigen received (as indi-
cated by transcription level in eggs) governing the level of IgE
suppression. The data for SmHSP20 suggest that there may also
be another mechanism for regulating deleterious IgE responses in
which large quantities of IgG4 are produced in the absence of IgE
down-regulation, the reasons for which require further investiga-
tion. The parallels between SIT and the natural immune response
to chronic S. mansoni infection described here and elsewhere high-
light the similarities between the immune responses to metazoan
parasites and allergens and provide further evidence for the evolu-
tionary origins of allergy-like responses in the immune reactions
against metazoan parasites.
Our data, supporting the hypothesis that molecular struc-
tures associated with metazoan parasites determine the allergen
landscape, have broad implications for the evolution and func-
tion of the IgE response consistent with its role of protection
against these organisms. Endo- and ecto-macroparasites would
have placed strong evolutionary pressure on the immune system,
and specialized molecular mechanisms are likely to have developed
to rapidly expand IgE responsiveness during parasite challenge
and regulate harmful IgE-mediated immune responses. Whether
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operating through an antigen-specific mechanism, or invoking a
new set of pathogen receptors, this hypothesis provides a novel,
testable, explanation of allergy and allergens (54). In this setting, a
more detailed analysis of functionally diverse S. mansoni antigens,
guided by a structural bioinformatics pipeline based on known
allergen structures, may provide a clearer picture as to the complex
relationship between IgE production, regulatory IgG4 responses,
and protective responses to the parasite and help elucidate the
mechanisms of IgE targeting in both parasitic disease and allergy.
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